OriGene to add antibody expertise with $16M SDIX deal

04/9/2013 | GenomeWeb Daily News (free registration)

SDIX will sell its life science assets to OriGene Technologies for $16 million. The deal is expected to be finalized this quarter. SDIX's knowledge in antibody development and production "will complement OriGene's existing high-throughput monoclonal antibody capacity to develop the highest quality antibodies," OriGene Chairman and CEO Wei-Wu He said.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA